Evonik's stock surges 10% in a week on chemical shortages and CEO reforms
Evonik's stock has climbed sharply over the past week, rising nearly 10 percent in five trading days. On Friday alone, shares jumped another 6 percent as investors reacted to the company's improving financial outlook and strategic changes under CEO Christian Kullmann. The recent surge in Evonik's share price follows a global shortage of C4 chemicals and methionine, key products for the company. With demand outstripping supply, prices in Europe and the U.S. have soared, allowing Evonik to capitalise on higher margins. The firm's production sites, located outside crisis zones, have also helped maintain steady output.
CEO Christian Kullmann's cost-cutting efforts, including restructuring and job reductions, have further strengthened the company's financial position. At the same time, Evonik is streamlining its operations by divesting or spinning off non-core divisions. The goal is to create a more focused specialty chemicals business. Several major investment banks have taken notice of these developments. Morgan Stanley recently raised its price target for Evonik to €18, reflecting growing confidence in the company's future performance.
The combination of strong market conditions and internal restructuring has driven Evonik's stock to its highest level in months. Analysts now expect the company to maintain its momentum as it refines its business model and benefits from sustained demand for its key products.
